Optimization of Extended-Release ZL-004 Nanosuspensions for In Vivo Pharmacokinetic Study to Enhance Low Solubility and Compliance.

Molecules · 2018 · PMC6337511 · PMID 30577480

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

The t 1/2 of NS-PC-S with the larger particle size demonstrated a marginally significant increase compared with NS-PB-S, and the mean days of attaining therapeutically effective plasma concentration increased from 27 days to 32 days.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.